Integrity Alliance LLC. purchased a new position in The Clorox Company (NYSE:CLX - Free Report) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 2,845 shares of the company's stock, valued at approximately $419,000.
A number of other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in shares of Clorox by 0.4% during the 1st quarter. Vanguard Group Inc. now owns 15,573,076 shares of the company's stock valued at $2,293,135,000 after purchasing an additional 65,924 shares during the last quarter. Northern Trust Corp grew its holdings in shares of Clorox by 2.3% during the 1st quarter. Northern Trust Corp now owns 1,528,920 shares of the company's stock valued at $225,133,000 after purchasing an additional 34,655 shares during the last quarter. Invesco Ltd. raised its position in Clorox by 7.4% in the 1st quarter. Invesco Ltd. now owns 1,361,710 shares of the company's stock worth $200,512,000 after purchasing an additional 94,371 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in Clorox by 3.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,157,257 shares of the company's stock worth $170,406,000 after purchasing an additional 41,485 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Clorox by 12.4% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,115,772 shares of the company's stock valued at $181,213,000 after buying an additional 123,200 shares during the period. Institutional investors own 78.53% of the company's stock.
Analysts Set New Price Targets
Several research analysts have recently commented on CLX shares. Citigroup reiterated a "neutral" rating and issued a $135.00 price objective (down previously from $140.00) on shares of Clorox in a report on Tuesday, July 15th. Jefferies Financial Group dropped their price objective on Clorox from $167.00 to $145.00 and set a "buy" rating for the company in a research note on Thursday, June 26th. Morgan Stanley cut their target price on shares of Clorox from $150.00 to $137.00 and set an "equal weight" rating on the stock in a report on Friday, August 1st. Barclays lowered their price target on shares of Clorox from $129.00 to $119.00 and set an "underweight" rating for the company in a report on Tuesday, July 15th. Finally, Wells Fargo & Company cut their price target on shares of Clorox from $138.00 to $130.00 and set an "equal weight" rating on the stock in a report on Friday, September 5th. One investment analyst has rated the stock with a Buy rating, eight have issued a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Reduce" and a consensus price target of $142.18.
Read Our Latest Report on CLX
Insider Transactions at Clorox
In other Clorox news, COO Eric H. Reynolds sold 15,041 shares of Clorox stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $123.78, for a total value of $1,861,774.98. Following the completion of the sale, the chief operating officer owned 54,221 shares of the company's stock, valued at approximately $6,711,475.38. The trade was a 21.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.57% of the company's stock.
Clorox Stock Down 0.4%
Shares of Clorox stock traded down $0.44 on Thursday, reaching $124.96. The company's stock had a trading volume of 516,756 shares, compared to its average volume of 1,658,221. The Clorox Company has a 52 week low of $116.53 and a 52 week high of $171.37. The firm's fifty day simple moving average is $124.21 and its two-hundred day simple moving average is $131.81. The company has a quick ratio of 0.57, a current ratio of 0.84 and a debt-to-equity ratio of 5.15. The company has a market capitalization of $15.28 billion, a price-to-earnings ratio of 19.15, a P/E/G ratio of 1.00 and a beta of 0.52.
Clorox (NYSE:CLX - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $2.87 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.24 by $0.63. Clorox had a return on equity of 377.86% and a net margin of 11.40%.The firm had revenue of $1.99 billion for the quarter, compared to the consensus estimate of $1.94 billion. During the same period in the prior year, the company posted $1.82 earnings per share. The company's quarterly revenue was up 4.5% on a year-over-year basis. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Equities analysts anticipate that The Clorox Company will post 7.15 earnings per share for the current year.
Clorox Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Thursday, November 6th. Investors of record on Wednesday, October 22nd will be issued a $1.24 dividend. The ex-dividend date is Wednesday, October 22nd. This represents a $4.96 annualized dividend and a yield of 4.0%. Clorox's dividend payout ratio (DPR) is currently 76.07%.
Clorox Profile
(
Free Report)
The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.
See Also

Before you consider Clorox, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Clorox wasn't on the list.
While Clorox currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.
Get This Free Report